BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 18, 2015
View Archived Issues
Long-term data for olokizumab in rheumatoid arthritis
Read More
Tolerability of pevonedistat with docetaxel, paclitaxel/carboplatin or gemcitabine
Read More
Otsuka Pharmaceutical reviews highlights of third quarter 2015
Read More
Antibe licenses Knight Therapeutics rights for pain and inflammation drugs
Read More
MGB Biopharma completes feasibility study of topical MGB-BP-3
Read More
Cinfa Biotech treats first subjects with biosimilar pegfilgrastim
Read More
ProMetic reveals agent under development for diabetic nephropathy
Read More
First-in-patient data for anti-fractalkine MAb E-6011 in RA
Read More
Phase I results for FPA-008 in RA
Read More
Pfizer discloses antineoplastic compounds
Read More
Roche patents TAAR1 ligands
Read More
Medshine Discovery presents ROCK inhibitors
Read More
Shanghai Institute Materia Medica divulges KCNQ2 activators
Read More
Jiangsu Kanion Pharmaceutical and Medshine Discovery report anti-EV71 compounds
Read More
Genoscience's first-in-class autophagy inhibitor GNS-561
Read More
Tragara and Lee's Pharma to develop TG-02 in China and South East Asia
Read More
Genentech opts-in to the Ophthotech/Novartis ex-U.S. agreement for Fovista
Read More
European Commission approves expanded uses of Kalydeco for cystic fibrosis
Read More
Turing initiates phase I trial of TUR-004 for epileptic encephalopathies
Read More
Gemphire Therapeutics presents preclinical and clinical data for gemcabene
Read More
Phase II results with hepcortespenlisimut-L in HCC lead to phase III trial
Read More
Vigilant Biosciences receives CE mark for OncAlert oral cancer CD44/total protein lab test
Read More
MRG-106 enters phase I trial in patients with CTCL
Read More
Depomed licenses rights to Gruenenthal's analgesic cebranopadol
Read More
Actinium files IND for phase III trial of Iomab-B
Read More
Summit Therapeutics and University of Oxford extend utrophin collaboration
Read More
FDA grants orphan drug designation to Amyndas Pharmaceuticals' Compstatin 40
Read More